| Reiss, Gary |
NCT06379893: A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain |
|
|
| Active, not recruiting | 4 | 195 | Europe, US | Voltaren Gel 1% (diclofenac sodium) (US only), Voltaren Gel 1.16% (diclofenac diethylammonium) (EU only), Voltaren Gel 2.32% (diclofenac diethylammonium) (EU only) | HALEON | Pain | 10/24 | 10/24 | | |
NCT05303636: LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women |
|
|
| Recruiting | 4 | 1710 | US | LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet | Insud Pharma, Chemo Research | Change in Bone Mineral Density, Bone Loss | 07/26 | 03/27 | | |
| Recruiting | 3 | 612 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc., Galectin Therapeutics Inc | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
NCT05591079: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH |
|
|
| Completed | 2 | 99 | US | CS0159 (Linafexor), placebo | Cascade Pharmaceuticals, Inc, Laboratory Corporation of America | Nonalcoholic Steatohepatitis (NASH) | 11/23 | 11/23 | | |
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 42 | Europe, US | IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | 03/24 | 06/24 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
GLY-200-03, NCT06259981: A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity |
|
|
| Active, not recruiting | 2 | 75 | US | GLY-200, Placebo | Glyscend, Inc. | Obesity | 12/24 | 12/24 | | |
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis |
|
|
| Active, not recruiting | 2 | 219 | US | HU6, Placebo | Rivus Pharmaceuticals, Inc. | Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver | 02/25 | 04/25 | | |
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease |
|
|
| Not yet recruiting | 2 | 393 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Liver Diseases, Alcoholic | 12/26 | 03/27 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Recruiting | 2 | 48 | US | GSK4532990 | GlaxoSmithKline | Non-alcoholic Fatty Liver Disease | 06/25 | 06/25 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain |
|
|
| Recruiting | 2 | 384 | US | RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo | Reata, a wholly owned subsidiary of Biogen | Diabetic Peripheral Neuropathic Pain | 08/26 | 08/26 | | |
| Recruiting | 1/2 | 73 | US | REC-4881, Placebo | Recursion Pharmaceuticals Inc. | Familial Adenomatous Polyposis | 07/26 | 07/26 | | |
NCT05743010: A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 1b | 36 | US | APL-1401, Nepicastat, SYN117, Placebo | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Ulcerative Colitis | 03/25 | 04/25 | | |
NCT05490888: Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics |
|
|
| Recruiting | 1 | 62 | US | PHIN-214 Subcutaneous injection, Terlipressin derivative | PharmaIN | Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic | 10/25 | 12/25 | | |
| Recruiting | N/A | 925 | US | Blood glucose meter, Eversense CGM System | Senseonics, Inc. | Diabetes | 03/26 | 03/26 | | |
